Nanoparticle-Wrapped Herbal Compound Shields Rat Livers From Arsenic Damage

Arsenic is one of the most insidious contaminants on Earth. It leaches from natural mineral deposits, seeps into groundwater through mining and smelting operations, and lingers in pesticides and industrial waste. Most of its compounds are colorless, odorless, and tasteless, which means millions of people can be exposed chronically without ever knowing it. The liver, as the body’s central detoxification organ, takes a heavy toll from this exposure, and a new study published in BMC Pharmacology and Toxicology suggests that an old herbal remedy, upgraded with modern nanotechnology, may offer powerful protection.

The compound at the center of the research is puerarin, an isoflavone extracted from the root of the kudzu vine, a plant long used in traditional Chinese medicine. Puerarin has already attracted attention for its antioxidant and anti-inflammatory properties, and previous studies have linked it to protection of heart, brain, and liver tissue. The problem is that puerarin is a notoriously difficult drug to deliver. It dissolves poorly in water, degrades quickly in the body, and is metabolized so rapidly that very little of an oral dose ever reaches target tissue. These pharmacokinetic weaknesses have kept it out of mainstream clinical use despite two decades of promising laboratory data.

To overcome that barrier, a team of researchers from Saudi Arabia and Egypt, led by Shaza Alyamani of Batterjee Medical College and Gehad Elshopakey of Mansoura University, encapsulated puerarin inside nanoparticles made of poly(lactic-co-glycolic acid), or PLGA, a biodegradable polymer already approved by regulators for use in drug delivery and medical devices. The resulting particles were remarkably uniform: roughly 69 nanometers in diameter on average, with individual particles ranging between 46 and 65 nanometers, a narrow size distribution, and a strongly negative surface charge that keeps them from clumping together. Using a modified nanoprecipitation and solvent evaporation technique, the team achieved an encapsulation efficiency of about 84 percent and a drug loading of 8.5 percent, meaning the tiny particles carry a substantial cargo of the active compound.

Laboratory release tests revealed why the formulation matters so much. Free puerarin dumped nearly all of its payload within 24 hours in a burst that would be wasted in the bloodstream. The PLGA-encapsulated version released only about 8 percent initially and then trickled out steadily, reaching roughly 52 percent at 12 hours and about 91 percent over 72 hours. That sustained profile means the drug stays in circulation longer, and Fourier transform infrared spectroscopy confirmed that puerarin and the polymer interact only through non-covalent forces, preserving the chemical integrity of both components.

With the formulation validated, the researchers turned to an animal model of arsenic poisoning. Sixty male Sprague-Dawley rats were randomly divided into six groups. One group served as untreated controls, two groups received free puerarin or the nanoparticle formulation alone, one group received arsenic at 10 milligrams per kilogram of body weight orally for 14 days to induce subacute liver injury, and two groups received arsenic alongside either free puerarin or the nanoformulation at an equivalent dose of 100 milligrams per kilogram. The study was designed with a formal power analysis and followed international ethical standards for animal research, including OECD guidelines and ARRIVE recommendations.

The arsenic-only animals showed all the classic signatures of a poisoned liver. Serum levels of the liver enzymes ALT, AST, and ALP surged, indicating that hepatocyte membranes had ruptured and leaked their contents into the blood. Albumin and total protein dropped, reflecting a failing synthetic capacity, and the lipid profile deteriorated in a pattern consistent with mitochondrial dysfunction. At the molecular level, the picture was even more striking. Arsenic exposure flooded liver cells with reactive oxygen species, oxidized DNA, as measured by the marker 8-OHdG, and drove iron accumulation. Crucially, the rats’ livers showed a coordinated collapse of the antioxidant machinery that normally guards against a recently recognized form of cell death called ferroptosis, an iron-dependent process in which lipid membranes are destroyed by runaway peroxidation. The ferroptosis-suppressing proteins GPX4 and SLC7A11 were sharply downregulated, while the pro-ferroptotic enzymes ACSL4 and transferrin receptor 1 climbed, alongside mounting levels of lipid peroxidation products such as MDA and 4-HNE.

Both forms of puerarin pushed back against this molecular storm, but the nanoparticle version did so more decisively. PU-PLGA treatment restored the SLC7A11/GPX4 axis, boosted nuclear levels of the master antioxidant regulator NRF2, slashed hepatic iron, and normalized markers of lipid peroxidation to near-control values. It also quieted the inflammatory cascade, suppressing NF-κB signaling and lowering the cytokines TNF-α, IL-6, and IL-1β, along with the enzyme COX-2. Fibrotic signaling, marked by TGF-β and collagen type I, retreated as well. The nanoformulation outperformed free puerarin on nearly every measure, and the differences between the two treatments were statistically significant for most biomarkers, including NRF2, GPX4, ACSL4, TNF-α, and the fibrosis markers.

Perhaps most striking were the cell-death pathways. Arsenic tipped the apoptotic balance toward death by raising pro-apoptotic Bax and caspase-3 while depleting the survival proteins Bcl-2 and phosphorylated AKT. PU-PLGA reversed this imbalance, restoring anti-apoptotic signaling more effectively than the crude compound. The benefits were visible under the microscope, too. Light microscopy revealed that arsenic-treated livers suffered dilated sinusoids, hepatocyte vacuolation, and necrotic nuclei, while transmission electron microscopy showed swollen mitochondria with shattered cristae and dilated endoplasmic reticulum. In the nanoparticle-treated animals, hepatic architecture and mitochondrial ultrastructure were largely preserved, and immunohistochemistry confirmed robust restoration of GPX4 in hepatocytes alongside suppression of ACSL4 staining.

The authors are appropriately careful about interpretation. They note that the ferroptosis findings rely on ELISA-based biomarkers rather than direct functional validation with lipid-reactive-oxygen-species probes or ferroptosis inhibitors such as ferrostatin-1, so the data support ferroptosis-associated pathway modulation rather than definitive proof of ferroptotic cell death being blocked. Similarly, pharmacokinetic measurements of puerarin levels in blood and liver were not performed, so the superior performance of the nanoformulation, while plausibly attributable to sustained release and improved bioavailability, cannot yet be pinned to a specific mechanism. The study also used only male rats over a short two-week window, leaving questions of sex differences and long-term fibrosis progression open for future work.

Even with those caveats, the study is a compelling demonstration of how nanotechnology can rescue a pharmacologically gifted but delivery-challenged natural product. By wrapping puerarin in biodegradable PLGA shells, the researchers achieved simultaneous suppression of oxidative stress, ferroptosis-related signaling, inflammation, apoptosis, and early fibrotic remodeling in a living model of arsenic hepatotoxicity. For the millions of people worldwide whose drinking water carries dangerous levels of arsenic, the work offers a proof of concept that a kudzu-derived isoflavone, delivered at the nanoscale, could one day become a genuinely protective therapy. Translational validation, safety profiling, and human pharmacokinetic studies remain the necessary next steps, but the groundwork is now firmly in place.

Subject of Research: Hepatoprotective effects of PLGA-loaded puerarin nanoparticles against arsenic-induced liver injury through modulation of ferroptosis and oxidative stress

Article Title: PLGA-loaded puerarin attenuates arsenic-induced liver injury through modulation of ferroptosis, oxidative stress, inflammation, and apoptotic signaling

Article References: Alyamani, S. A., Hifni, B. A., Alqahtani, N. S., Elmorsy, E. M., Al-Ghafari, A. B., Al Doghaither, H. A., Chatha, W. A., & Elshopakey, G. E. (2026). PLGA-loaded puerarin attenuates arsenic-induced liver injury through modulation of ferroptosis, oxidative stress, inflammation, and apoptotic signaling. BMC Pharmacology and Toxicology, 27(1), Article 129. https://doi.org/10.1186/s40360-026-01221-0

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01221-0

Keywords: puerarin, PLGA nanoparticles, arsenic, hepatotoxicity, ferroptosis, oxidative stress, Nrf2, GPX4, liver injury, nanomedicine, inflammation, apoptosis